Bristol-Myers Squibb (BMY) has started a new initiative with Tempus AI (TEM) to use artificial intelligence, multimodal real-world data, and data science techniques across five initial clinical trial programs, Tempus said Thursday.

The initiative will aim to optimize clinical trial designs and boost the success probability of key assets in solid tumor oncology, including lung, colon, and prostate cancers for the pharmaceutical company, Tempus said.

Financial terms of the initiative were not provided.